Sebastian Maier

Lilly Deutschland GmbH, Germany

Poster(s):

• P1210 - Subcutaneous Mirikizumab Maintenance Treatment Over 40 Weeks Leads to Incremental Improvements in Rates of Clinical Remission and Endoscopic Response: Results From the Phase 3 VIVID-1 Study
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT